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Effects of 3,5,30-Triiodothyroacetic
Acid, Nanoencapsulated or Not,
on Intact and Atrophic Skin
in Rats
We aimed to investigate 3,5,30-triiodothyroacetic acid (TRIAC) effects on intact and
atrophic skin induced by glucocorticoids (GCs) in rats and the effects induced by nanoen-
capsulation. The effects of TRIAC and nanoencapsulated TRIAC were evaluated on intact
and atrophic skin in TRIAC experiment and nanoencapsulated TRIAC experiment,
respectively. Both experiments had two phases: phase I, cutaneous atrophy was induced;
phase II, TRIAC or nanoencapsulated TRIAC was administrated. Our results showed that
topical use of TRIAC with or without nanoencapsulation was able to reverse cutaneous
atrophy. Nanoencapsulated TRIAC showed less systemic changes than TRIAC; therefore,
it is possibly a safer drug for topical administration. [DOI: 10.1115/1.4028695]
Introduction
Skin atrophy is the most important adverse effect following
prolonged topical GCs use and it has been argued that deiodi-
nases, enzymes involved in thyroid metabolism, are essential for
GC-induced skin atrophy [1,2]. Thyroid is the main source of
thyroid hormones (THs) and secretes primarily 3,5,30,50-L-
tetraiodothyronine (tyroxine, T4) and a smaller amount of 3,5,30-
L-triiodothyronine (T3), that is mostly originated through the
extrathyroidal deiodinization of T4. As shown before in literature,
high dosages of GCs reduce the ratio of T3 to T4 in plasma by
blocking deiodinase-1 (D1) and deiodinase-2 (D2) and increasing
deiodinase-3 (D3) action [3]. D2 and D3 deiodinases are crucial
for intracellular THs control in skin, whereas D1 is not expressed
[4]. GCs inhibit the activity of D2 present in skin, leading to lower
concentrations of T3 and since T3 is about four to five times
biologically more active than T4, there is local hypothyroidism
followed by collagen synthesis reduction [5,6].
The TH binds to two main isoforms of specific nuclear recep-
tors, TRa and TRb, with different patterns of expression in devel-
oping and adult tissues [7]. TRa and TRb are present in normal
skin and knockout animals as these receptors have less epidermal
proliferation and increased expression of inflammatory cytokines
and chemokines, which emphasizes the importance of thyroid
action on skin physiology [8,9]. Taking this into account, TH is a
strategy for treating atrophic skin. The possibility of using
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selective ligands for different varieties of TH receptors is of clini-
cal relevance and may be interesting for the pharmaceutical
industry [10,11].
TRIAC is a T3 acetic acid metabolite and represents 2% of cir-
culating THs. It is present in various tissues and is a selective acti-
vator of TRb [12,13]. TRIAC has been used to increase the
metabolic rate and induce weight loss [14]. Topical application of
TRIAC increases skin thickness and is capable of reversing skin
atrophy induced by GC in mouse models [15]. An increased syn-
thesis of procollagen in human skin treated with topical TRIAC
was also observed [16].
The stratum corneum, which is the nonviable uppermost layer
of the epidermis, is an obstacle for the delivery of many molecules
at therapeutic levels. Drug transport across the stratum corneum is
complex. Therefore, in order to enhance the transfer of a molecule
across this layer, parameters such as partition, diffusion, and solu-
bility coefficients need to be manipulated and targeted. In addi-
tion, aspects related to physicochemical and pharmacokinetic
properties and linkage capability with cell membrane also influ-
ence molecular penetration–absorption of specific drugs [17].
Nanotechnology has emerged as an important tool in medicine,
especially in drug carrier and delivery systems development,
which may affect the bioavailability of the active molecule and
improve its therapeutic efficacy [18,19]. The technological
development of new administration forms has been a promising
strategy to increase and control drug skin penetration [20,21]. In
the past years, different strategies have been proposed to increase
drug skin permeation and to circumvent the inadequate physico-
chemical characteristics of several substances. Nanometric sys-
tems have a great surface area, which renders them highly
satisfactory for the application of lipophilic substances, promoting
a homogeneous drug release. Nanostructured systems for drug
release are basically colloidal aqueous suspensions containing
nanospheres, nanocapsules, nanoemulsion, solid lipid nanopar-
ticles, microemulsions, liposomes, or niosomes [22].
Using polymeric materials for encapsulating drugs or other
active agents can help to hide physicochemical properties of these
substances, facilitating skin penetration [23]. Polymeric nanopar-
ticles for drug release usually refer to carrier systems comprising
nanocapsules or nanospheres with diameters lower than 1 lm. The
basic difference between the latter systems is the type of entrap-
ment of the active material by the polymeric agent. For nano-
spheres, the combination of active molecule and polymer forms a
matrix pattern structure and the active molecule is homogeneously
dispersed or solubilized within the polymer matrix. On the other
hand, nanocapsules are reservoirs and the active molecule is sur-
rounded by a polymeric membrane, insulating the core from the
external environment. Choosing the best nanostructured system
depends on the type of material, application, and release mecha-
nism required for its action [22,24,25]. The polymeric shell of the
nanocapsules can be design in order to improve their biodistribu-
tion profile and to extend the half-life of the encapsulated mole-
cule. Moreover, the nanocapsules can be formulated to be more
stable over time compared to nanospheres which lose their stabil-
ity and active molecule easily [26]. An efficient nanostructured
system depends on the type of material to be encapsulated, appli-
cation, and release mechanism required for its action.
The aim of this study is to investigate the TRIAC effects on
intact and atrophic skin induced by GCs in rats, analyzing possible
differences depending on hormone presentation form: nanoencap-
sulated or not.
Methodology
Animals. Fifty-two Wistar male rats (Rattus norvegicus albi-
nus, Rodentia mammalian), weighing 250–280 g, were kept in
individual cages in a room with a controlled temperature, humid-
ity, and lighting (lights on from 0600 to 1800 h), with free access
to food and water and were allowed to adapt to the environment
for 3 days prior to the experiments. The study outline and
procedure was approved by the Institutional Animal Research
Ethical Committee (Document No. 034/2009).
Experimental Design. The effects of TRIAC (TRIAC experi-
ment) and nanoencapsulated TRIAC (nanoencapsulated TRIAC
experiment) were evaluated on intact and atrophic skin. In each
experiment, 24–32 aged and size-matched Wistar rats were used.
Each experiment was carried out in two phases. In phase I, ani-
mals were divided into two groups (12–15 rats in each group): in
group 1, animals remained with intact skin; in group 2, cutaneous
atrophy was induced by topical administration of Clobetasol pro-
pionate for 10 days. In phase II, each group of animals with
atrophic or intact skin were subdivided into two subgroups A and
B (4–8 rats in each subgroup): in subgroups 1 A and 2 A, the vehi-
cle was used; in subgroups 1B and 2B, TRIAC or nanoencapsu-
lated TRIAC was administered daily for 14 days, depending on
the experiment (TRIAC in the first experiment and nanoencapsu-
lated TRIAC in the second experiment).
The experimental design is illustrated in Fig. 1. During 26 days,
the animals’ weight, temperature, and food intake were measured
in the morning, between 8:00 and 10:00 AM, every other day, by
the same person. Three cutaneous biopsies were taken from the
dorsal area of each animal on experimental days 0, 11, and 26. At
the end of the experiments, animals were sacrificed and retroperi-
toneal and epididymal fat were removed and weighed immedi-
ately. Blood samples were collected, and T3 and free T4
measurements were performed in plasma samples stored at
20 C, using a chemiluminescence method.
Drugs. TRIAC was obtained from Sigma Aldrich Corporation.
For TRIAC experiment, the hormone was diluted in a 50–50
alcohol–water solution for a final concentration of 10 nmol/cm2
and the vehicle was diluted in a 50–50 alcohol–water solution that
was applied to the vehicle group.
For nanoencapsulated TRIAC experiment, TRIAC was nanoen-
capsulated in a poly(D,L-lactide) (PLA) polymer developed by the
Nanomedicine and Nanotoxicology Group from the Physics Insti-
tute of S~ao Carlos, University of S~ao Paulo. The nanoencapsula-
tion technique utilized was an adaptation from the coprecipitation
method combined with nanoprecipitation by solvent evaporation,
with a 98% yield [27,28]. For the encapsulation process, an aque-
ous solution with PLA polymer was mixed to an organic solution
containing 20 nM TRIAC in order to induce immediate capsular
formation by enclosing the active hormone in its nucleus. As a
result of this process modification, there was no need to use sur-
factant or oil to obtain the nanoencapsulated material. The result
of this encapsulated process revealed that the average diameter of
the nanocapsules without TRIAC was 1606 37 nm and polydis-
persion index (PdI) was 0.1086 0.024. For nanocapsules contain-
ing TRIAC, the average diameter increased to 2316 59 nm and
PdI to 0.0626 0.009, indicating a high stability of nanocapsules-
TRIAC generated by this process. The nanocapsules containing
the active were resuspended in ultrapure water (MilliQ) in a final
concentration of 10 nM, once conformational instability was
detected using alcoholic solution. Moreover, it was used in a con-
centration of 10 nmol/cm2. The vehicle in this experiment was
composed of PLA polymer resuspended in water.
Skin Histopathology. Punch skin biopsies were immediately
wrapped in individual pre-identified recipients with 10% buffered
formaldehyde. After tissue fixation, each biopsy was separated in
two halves and one fragment was stored while the other one was
submitted to histological processing, including: dehydration in
ethanol, clearing in xylem, and embedding in paraffin. At least
three serial histological sections (4 lm thick) were obtained per
biopsy and stained with hematoxylin and eosin (HE) or picrosirius
red for microscopic examination.
Images were captured and analyzed by a system composed of a
video camera coupled to an Olympus BX51 microscope, which
was linked to a microcomputer with an image digitalizing plate
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and UTHSCSA IMAGETOOL software, version 3.0 (program developed
at the University of Texas Health Science Center at San Antonio,
TX and available from the Internet by anonymous FTP).2 Five
captures of the slides stained with HE were performed at 400
times magnification for epidermal evaluation and another five cap-
tures of the slides stained with picrosirius were done for dermal
evaluation.
Slides stained with HE were coded and blindly evaluated for
epidermal thickness. The thickness of the epidermis (in lm) was
measured at five different points in three different sections per
biopsy. The mean value was calculated and considered as final.
Slides stained with picrosirius red were examined under polar-
ized light and classified as 0, 1, or 2, meaning no dermal change,
dermal partial atrophy, and intense dermal atrophy, respectively.
This histological score was based on the extracellular matrix
architecture and the outlook of dermal collagen fibers. Collagen
type I fibers were recognized in picrosirius staining by their bire-
fringence and red tonality, while collagen type III fibers were seen
as less birefringent and yellow–green fibers. The histological
appearance of sections classified as 0 showed cytological and ar-
chitectural characteristics similar to the normal adjacent dermis,
meaning no atrophic changes. The slides classified as 1 were the
ones that presented the following alterations in 25–50% of the
dermal cells: reduced thickness of collagen fibers type I
(1.0–20.0 lm) and type III (<0.5–2.0lm) and increased ratio of
collagen fibers type I to type III (normal values of 80–85% type
I/15–20% type III). The slides classified as 2 were the ones with
intense atrophy, meaning the tissue analyzed had the same charac-
teristics described above in a percentage greater than 50% of the
cells [29,30].
Results were presented as mean6 standard error of the mean or
percentage. Differences between groups were assessed by Wil-
coxon Mann–Whitney or Fischer exact tests, depending on the
variable analyzed. The level of significance was set at p< 0.05.
Results
Physiologic parameters are illustrated in Table 1. There was not
a significant statistical difference in temperature among the groups
in both experiments. TRIAC topical administration determined, in
animals with atrophied skin, a significant (p< 0.05) increase in
cumulative food ingestion and a decrease in retroperitoneal fat
weight, without any difference in weight gain. Nevertheless, nano-
encapsulated TRIAC resulted in only an isolated decrease in weight
Fig. 1 Schematic representation of experimental design. Each experiment was carried out in two
phases. In phase I, animals were divided into two groups: in group 1, animals remainedwith intact
skin; in group 2, cutaneous atrophy was induced by topical administration of Clobetasol propio-
nate for 10 days. In phase II, each group of animals with intact (group 1) or atrophic skin (group 2)
was subdivided 2 subgroups: in subgroups A, the vehicle was used; in subgroups B, TRIAC
or nanoencapsulated TRIAC was administered daily for 14 days, depending on the experiment.
Table 1 Physiological parameters in experiments 1 and 2
TRIAC experiment Nanoencapsulated TRIAC experiment
Intact skin (group 1) Atrophic skin (group 2) Intact skin (group 1) Atrophic skin (group 2)
Physiological
parameters
Vehicle
(subgroup 1 A)
TRIAC
(subgroup 1B)
Vehicle
(subgroup 2 A)
TRIAC
(subgroup 2B)
Vehicle
(subgroup 1 A)
NANO TRIAC
(subgroup 1B)
Vehicle
(subgroup 2 A)
NANO TRIAC
(subgroup 2B)
Temperature (C) 36.16 0.26 36.076 0.34 36.276 0.23 36.36 0.22 36.736 0.22 36.806 0.20 36.936 0.24 36.516 0.24
Mean weight
gain (g/100 g)
16.106 1.04 14.066 1.62 21.426 1.35 21.716 1.41 26.516 2.01 31.466 1.80 53.186 1.52 45.506 1.27*
Cumulative food
ingestion (g/100 g)
147.26 0.95 1516 4.18 154.86 4.57 167.86 7.05* 197.66 6.35 199.66 4.33 246.56 3.03 234.16 3.19
Epididymal fat
(g/100 g)
0.946 0.04 0.846 0.05 1.036 0.06 0.926 0.06 0.836 0.02 0.896 0.04 1.096 0.15 1.006 0.04
Retroperitoneal
fat (g/100 g)
0.686 0.03 0.636 0.05 0.786 0.05 0.536 0.06* 0.886 0.1 0.856 0.07 1.096 0.29 0.926 0.07
*p< 0.05
2maxrad6.uthscsa.edu
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Fig. 2 Effects of vehicle or TRIAC/nanoencapsulated TRIAC in epidermal thickness of rats
with intact or atrophic skin—data are represented as mean6SE (bars). In TRIAC experiment:
intact skin vehicle (subgroup 1A), intact skin TRIAC (subgroup 1B), atrophy skin vehicle (sub-
group 2A), and atrophy skin TRIAC (subgroup 2B). In nanoencapsulated TRIAC experiment:
intact skin vehicle (subgroup 1A), intact skin nanoencapsulated TRIAC (subgroup 1B),
atrophic skin vehicle (subgroup 2A), and atrophic skin nanoencapsulated TRIAC (subgroup
2B). *p<0.05.
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gain in animals with atrophied skin. There were no differences in
epididymal fat weight among groups in both experiments.
T3 levels were significantly higher and free T4 were signifi-
cantly lower (p< 0.0001) in animals treated with TRIAC (TRIAC
experiment), compared to those treated with vehicle. On the other
hand, in nanoencapsulated TRIAC experiment, there was no
difference between T3 and free T4 levels in animals treated
with nanoencapsulated TRIAC compared to those treated with
vehicle.
At the end of phase I in both experiments, there was a signifi-
cant decrease in the epidermal thickness after topical GC use
(p< 0.0001), confirming the induction of epidermal atrophy.
In TRIAC experiment, the mean values of epidermal thickness,
before and after vehicle administration, were, respectively:
2.876 0.23lm and 2.426 0.18lm in the intact skin subgroup
(1 A) and 2.206 0.46lm and 1.956 0.37lm in the atrophic skin
subgroup (2 A). The mean values of epidermal thickness, before
and after TRIAC topical administration, were, respectively:
2.716 0.30lm and 2.356 0.05lm in the intact skin subgroup
(1B) and 1.206 0.1lm and 1.856 0.13lm in the atrophic skin
subgroup (2B). There was no difference in the epidermal thick-
ness among animals with atrophic skin neither among animals
with intact skin before TRIAC or vehicle administration (begin-
ning of phase II). Epidermal thickness increased significantly after
TRIAC topical administration in animals from the atrophic group
(p< 0.0335). There was no significant difference in epidermal
thickness at the end of phase II among other groups. Figures 2
and 3 illustrate these results.
In nanoencapsulated TRIAC experiment, the mean values of epi-
dermal thickness, before and after vehicle topical administration,
were respectively: 3.256 0.48lm and 3.256 0.48lm in the intact
skin subgroup (1 A) and 2.066 0.35lm and 2.916 0.19lm in the
atrophic skin subgroup (2 A). The mean values of epidermal thick-
ness, before and after nanoencapsulated TRIAC topical administra-
tion, were, respectively: 2.566 0.13lm and 2.406 0.10lm in
intact skin subgroup (1B) and 1.716 0.23lm and 2.186 0.13lm
in atrophic skin subgroup (2B). There was no significant difference
in epidermal thickness among groups (Figs. 2 and 3).
Concerning the dermis, GC use resulted in significant skin atro-
phy in both experiments (p< 0.0001).
In TRIAC experiment, at the end of phase II, 33% of animals
treated with vehicle did not show dermal atrophy reversion and
67% had partial reversion. On the other hand, 44% of the animals
treated with TRIAC did not present dermal atrophy reversion,
28% had partial reversion, and 28% had total atrophy reversion. It
should be mentioned that not a single animal treated with vehicle
had total atrophy dermal reversion (Fig. 4).
In nanoencapsulated TRIAC experiment, at the end of phase II,
100% of animals treated with vehicle did not show dermal atrophy
reversion, although 14% of the animals treated with nanoencapsu-
lated TRIAC showed partial reversion and 86% had total atrophy
reversion. There was a significant increase in the degree of dermal
skin atrophy reversal in animals that used nanoencapsulated
TRIAC as compared to vehicle (p< 0.0001) (Fig. 4).
Discussion
In this work, systemic effects of topical TRIAC (nanoencapsu-
lated or not) were evaluated by the following parameters: temper-
ature, weight gain, food ingestion, and epididymal and
retroperitoneal fat weight.
The mean temperature of experimental animals was not modi-
fied by TRIAC topical administration. It is known that THs exert
their actions in almost every body cell and are responsible for
increasing lipid metabolism and oxygen consumption, as well as
having essential actions in specific systems such as cardiovascular
system, causing tachycardia, arrhythmias, and cardiac hypertro-
phy. The expected effects of therapies that lead to hyperthyroid-
ism are: decreased weight and increased appetite due to high
energy expenditure, reduced fat stores, and increased basal body
temperature [31]. Although the thermogenic effects of topical
TRIAC are not well established, Yazdanparast et al. [16] did not
show a change in temperature in studies with humans, and labora-
tory parameters were within the normal range. Nonetheless, an
important thermogenic effect of TRIAC systemic administration
has been demonstrated by enhancing adrenergic stimulation of
uncoupling protein-1 mRNA in brown adipocytes, in vitro [32]
and in vivo [33]. One possible explanation for these findings is
that the TRIAC effects vary according to their dose and adminis-
tration route, and accordingly, the low doses of TRIAC applied
topically might not have been sufficient to cause significant
Fig. 3 Illustrative photomicrography of epidermal thickness at
the end of the experiments in different groups. In TRIAC experi-
ment: intact skin vehicle (subgroup 1A), intact skin TRIAC (sub-
group 1B), atrophic skin vehicle (subgroup 2A), and atrophic
skin TRIAC (subgroup 2B). In nanoencapsulated TRIAC experi-
ment: intact skin vehicle (subgroup 1A), intact skin nanoencap-
sulated TRIAC (subgroup 1B), atrophic skin vehicle (subgroup
2A), and atrophic skin nanoencapsulated TRIAC (subgroup 2B)
(4003).
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thermogenic effects. Additionally, in this study, the animal’s tem-
perature was evaluated by rectal measurements, once a day, every
other day, which might not be sufficient to reveal small tempera-
ture changes.
TRIAC did not modify the animal’s weight gain. Although,
there was a significant increase in cumulative ingestion in animals
with atrophic skin that had TRIAC administration compared to
those that had vehicle. This result, as well as the decrease in the
mean retroperitoneal fat weight in atrophic skin animals that used
TRIAC, suggests that the TRIAC dose used had a stimulatory
effect on food ingestion, possibly by decreasing leptin secretion
[32], but its lipolitic action resulted in a decline in retroperitoneal
fat deposits which resulted in maintaining the animals’ body
weight. The atrophy group received nanoencapsulated TRIAC has
decreased weight gain. More experiments need to be done to
confirm and better explain these data.
As for thyroid function evaluation, T3 values were higher in ex-
perimental groups treated with TRIAC than in groups that used
vehicle, suggesting that there was a cross reactivity between
TRIAC and the assay’s antibody, which was previously described
by Anzai et al. [34]. Additionally, thyroxine values (free T4) were
significantly reduced in the group of animals treated with TRIAC
suggesting that there was a suppression of endogenous hormone
production by systemic absorption of topically applied TRIAC, as
was previously described for topical T3 [35]. Experiments that
evaluated topical TRIAC to reverse skin atrophy did not show a
change in THs plasma levels both in humans [6] and in mice [36].
This could be attributed to methodological differences in drug
doses and the administration schedule. It may reflect differences
secondary to the animal species studied as in this work, rats were
used as experimental animals.
Our results showed a significant effect of TRIAC topical admin-
istration on reversing epidermal atrophy secondary to GC in line
with previous published data [16]. As for the mechanisms related
to this effect, Zhang et al. [37] suggested that TRIAC could act to
stimulate epidermal thickening in mice and keratinocyte prolifera-
tion in humans by activation of cyclin D1 expression.
TRIAC topical administration was also shown to result in sig-
nificant dermis thickness increase [15], collagen production, elas-
tic fibers synthesis, and dermal proliferation [31] similarly to what
was demonstrated by Safer et al. [38] with T3 topical use. Yaz-
danparast et al. [6] suggested that topical treatment with TRIAC
could restore skin local hypothyroidism induced by GC and thus
reverse impaired skin procollagen I expression. The dermal atro-
phy reversal found in this study could be the result of TRIAC
action on collagen synthesis [15,39] as suggested by histological
analyses of Picrosirius red staining material.
In our study, nanoencapsulated TRIAC did not show effects
significantly different from those observed with vehicle on epider-
mal thickness. On the other hand, animals that received
Fig. 4. Illustrative photomicrography of dermal appearance in picrosirius staining
histological slides: no atrophy reversion (a), partial atrophy reversion (b), and total
atrophy reversion (c) in TRIAC experiment; and no atrophy reversion (d), partial at-
rophy reversion (e), and total atrophy reversion (f) in nanoencapsulated TRIAC
experiment (4003).
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nanoencapsulated TRIAC were able to partially (14%) and fully
(86%) reverse dermal atrophy caused by GC, while animals
receiving vehicle showed no effect on dermal atrophy reversion.
These different effects on epidermis and dermis may be related to
the degree of skin penetration of the nanoencapsulated drug and/
or its higher activity in deeper skin layers as a result of their better
biodistribution profile and to the extended half-life of the encapsu-
lated TRIAC compared to the nonencapsuleted molecule as a
result of its lower degradation in epidermis [23,40]. It was demon-
strated that TRIAC is rapidly inactivated by skin deiodinases and
may have a short life in skin [41]. Another possibility is that the
process of atrophy, by changing skin function as a protective bar-
rier [42], facilitated nanoencapsulated TRIAC dermal penetration
[16].
Our results, based on physiological parameters and hormone
levels, suggested that there was a greater systemic TRIAC absorp-
tion compared to nanoencapsulated TRIAC, resulting in the inhi-
bition of endogenous thyroid function. Nevertheless, topical
application of nanoencapsulated TRIAC did not determine
changes in the hypothalamic–pituitary–thyroid axis. The finding
of an isolated decrease in weight gain in the atrophy group that
received nanoencapsulated TRIAC, compared to animals that
received vehicle, could be interpreted as a result of systemic cata-
bolic actions induced by this drug [31]. However, measurements
of cumulative food ingestion, visceral fat weight, and hormone
levels do not support this hypothesis and more studies are needed
to confirm and elucidate nanoencapsulated TRIAC action on
weight gain.
The results of this work show that topical use of TRIAC and
nanoencapsulated TRIAC determined significant reversal of der-
mal atrophy. Nanoencapsulated TRIAC may be a promising
option for the treatment of cutaneous atrophy, because of its
deeper layer skin action and less systemic effects, although further
studies are necessary to confirm this conclusion.
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